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SUMMARY 
Radiolabeled 19-iodocholesterol is widely used to obtain images of human adrenals. We have shown in 
rats and mice that 85-95% of the radiolabel is present in the esterified form. Using rat adrenal cytosolic 
cholesterol esterase, the kinetic parameters K~t and V were determined for commercially available 
cholesteryl [l-14C]-oleate (!) and [125I]-19-iodocholesteryl oleate (It). The Kra and V were found to be 
16.2/zM and 602 pmol/min/mg prot. respectively for I compared to 76.2 ttM and 37.6 pmol/min/mg prot. 
for II. Since V/Ku is 37.3 ml/min/mg prot. for the normal ester and 0.49ml/min/mg prot. for the 
iodinated analog, it appears that the normal substrate is 76 times more specific than II. In addition, 
direct competition experiments were run in which 67/~M I was used as substrate. The addition of 65 and 
325/tM 19-iodocholesteryl oleate caused 20 and 49% inhibition, respectively. On the basis of these 
studies, it is not surprising that 19-iodocholesterol would accumulate in the adrenals in an esterified 
form and thus provide an effective agent for adrenal visualization. 
INTRODUCTION 
In 1969 we reported the synthesis of [~2Sl]-19- 
iodocholest-5-en-3fl-oi ([ 125i]_ 19-iodocholesterol) and 
its ability to selectively concentrate in male dog adre- 
nals [1]. At 48 h following intravenous administra- 
tion, the concentration of radioactivity in the adrenals 
was 30 times that in liver and blood. Shortly after 
these studies, the first images of human adrenals were 
obtained with [131I]-19-iodocholesterol[2]. This 
agent has now been widely used to diagnose a variety 
of adrenal disorders in humans such as functional [3] 
and nonfunctional [4, 5] fidrenocortical carcinomas, 
primary aldosteronism [6], and Cushing's syn- 
drome [7]. This paper explores one facet of choles- 
terol metabolism that may account for 19-radioiodin- 
ated cholesterol's ability to act as an adrenal imaging 
agent. 
It is well known that, of all the organs, the adrenal 
gland has the' highest concentration of cholesterol. In 
the rat, for example, 5% of the net weight of the adre- 
nal cortex is comprised of cholesterol, most bf which 
is esterified[8]. There are potentially two major 
sources of cholesterol available to the cell to meet its 
metabolic needs: namely, that delivered directly by 
lipoproteins and that biosynthesized de novo from 
acetyl-CoA [9]. The cell also maintains a large store 
of cholesterol as esters which can be hydrolyzed to 
free sterol. 
In our early studies on the disposition of [125I]-19- 
iodocholesterol in dogs [1], we found most of the 
* To whom correspondence and reprint requests should 
be addressed. 
lipid extractable radioactivity from the adrenals to be 
associated with the cholesterol ester fraction. Simi- 
larly, later studies in female rats showed that greater 
than 90'~/0 of the radioactivity in both the adrenals and 
ovaries was present as radioiodinated cholesterol 
esters [10]. Clearly, in both dogs and rats, 19-iodo- 
cholesterol appears to mimic cholesterol in its ability 
to be taken up and esterified in those organs involved 
in steroidogenesis. Since cholesterol esters must first 
be hydrolyzed "to free cholesterol before they can be 
utilized for steroid hormone biosynthesis [11], it was 
of interest to ascertain the suitability of 19-iodo- 
cholesterol esters to serve as substrates for adrenal 
cholesterol esterase [EC 3.1.l.13]. We report here on 
the comparison of kinetic parameters (KM and V) for 
[125i].19_iodocholesteryl oleate and cholesteryl 
[l-f4C]-oleate using adrenal, cytosolic enzyme prep- 
arations. 
MATERIALS AND METHODS 
Materials 
[9,10-3H(N)]-Oleic acid (5.66Ci/mmol) and sub- 
strate, cholesteryl [l-14C]-oleate (51 mCi/mmol) were 
obtained from New England Nuclear, Boston, Mass. 
Aliquots from the original stock solution were diluted 
with either cholesteryl oleate or oleic acid, reagent 
grade, obtained from Sigma Chemical Company, until 
final activities were approximately 2.2 pCi/#mol and 
1 pCi//zmol for cholesteryl oleate and oleic acid re- 
spectively. Radiochemical purity of each solution was 
checked by thin layer chromatography, t.l.c., using the 
solvent system hexane-diethyl ether-glacial acetic 
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acid (80:20:1.75, v/v). 19-Iodocholesterol was a gift 
from Searle Laboratories, Skokie, Ill. Oleoyl chloride 
was from Nu-Cbek-Prep Co. ATP (99~o pure) and 
cAMP (97~ pure) were obtained from Sigma Chemi- 
cal Company. fl-Mercaptoethanol was obtained from 
Matbeson, Coleman and Bell. All other chemicals 
used in assays were of reagent grade. 
Preparation of 19=iodocholest-5-en-3fl-ol oleate 
A mixture of 19-iodocholesteroi (100rag, 
0.194mmol), oleoyl chloride (100mg, 0.332mmol) 
and triethylamine (20.2 m~ 0.200 mmol) in 25 ml of 
dry benzene was stirred at room temperature under 
N2 for 24 h. The solvent was removed in vacuo yield- 
ing a yellow residue which was stirred with 2 ml of 
H20 for 2 h. The aqueous mixture was then extracted 
three times with 100 ml of ether. The combined ether 
layers were washed with H20 and dried with 
Na2SO 4. Evaporation of the organic solvent yielded 
an oil that was purified on a 1.3 x 40 cm silica gel 
column using benzene as an eluant. 19-Iodocholest-5- 
en-3/~-ol oleate was isolated as a clear oil (130m~ 
86~o): I.R., V~x 1733cm=1; NMR, p.p.m. (CDCIa); 
0.84 (s, 3H, 18-CH3), 3.30 and 3.63 (dd, 2H, 19-CH2I), 
4.64 (m, 1H, 3~t-H), 5.38 (t, 2H, oleic vinyl H), 5.71 (m, 
1H, 6-H). Anal. Caled. C4sHv~O2I: C, 69.56; H, 9.99. 
Found: C, 69.62; H 9.78. 
Preparation of [12 s i]_19_iodocholest. 5.en.3 fl.ol oleate 
Aqueous Na[125I] (3.4 mCi, 250/*i) was placed in a 
15 ml round bottom flask and the H20 evaporated 
with a stream of N 2. 19-Iodocholest-5-en-3/~-ol oleate 
(8.4 rag, 10.8 retool) in 2 ml of dry acetone was added 
to the Na[12sI-J and the mixture was refluxed under 
N2 for 4 h. The acetone was evaporated with N2 and 
H20 (I ml) added to the flask. The aqueous phase was 
extracted with benzene (4 x 1 ml). The combined or- 
ganic layer was placed on a 1.4 x 4.5 cm silica gel 
column and eluted with benzene. A clear oil (7.0 rag, 
2.2 mCi) was isolated. Thin-layer chromatography of 
this product on Eastman Chromatogram silica gel 
plates with benzene showed a single spot (Re = 0.56) 
which co-migrated with authentic 19-iodocholest-5- 
en-3fl-ol oleate. Aliquots of [12sI]-19-iodocholesteryl 
oleate were diluted with stable material in acetone to 
a final concentration of 300/~Ci//*mol and stored at 
4°C until used. 
Under certain conditions 19-iodocholesterol has 
been shown to rearrange to 6fl-iodomethyl-19- 
norcholest-5(10)-en-3fl-ol [12, 13]. However, the nmr 
spectrum for 19-iodochoiesterol used in these studies 
agreed with published data [12, 14]. The subsequent 
isotope exchange reaction was performed in refluxing 
acetone, conditions which are known to not cause 
rearrangement [15]. In addition, rearrangement 
would not be expected to occur in vitro. 
Solutions 
The following is a description of the solutions used 
for either the cholesteryl esterase assays or for the 
enzyme preparation: Buffer I-0.25 M sucrose, 10 mM 
potassium phosphate (pH 7.4); Buffer II-0.25M su- 
crose, 10ram potassium phosphate (pH 7.4) and 
5 mM fl-mercaptoethanol; Cofactor solution-10mM 
MgC1.6H20, 100 mM Tris-HCl, 5 mM fl-mercapto- 
ethanol, 50raM KCI, 10raM Na2ATP.4.5 H20, 
0.2/*M dibutyryl cAMP, pH of this mixture was 
adjusted to 7.4 with 5% NaOH before addition to 
assay tubes. 
Enzyme preparation 
The procedure for enzyme preparation was a modi- 
fication of the method by Trzeciak and Boyd[16]. 
Adult female rats (200g), obtained from Spartan 
Research Animals Inc., Haslett, Mich., were sacrificed 
by ether overdose and the adrenals quickly removed 
and pooled in 5.0 ml Buffer I. Adrenals were homo- 
genized in 10 ml Buffer I and the homogenate trans- 
ferred to plastic Sorvall tubes and centrifuged as pre- 
viously described at 4°C. The resulting supernatant 
layer was then dialyzed at 4°C against Buffer II, 
2 x 500ml for 24h to remove endogenous lipid. 
The dialyzed crude preparation was stored in 0.5 ml 
aliquots at -20°C until needed. Protein concen- 
tration was determined by the method of Lowry and 
co-workers, as modified by Miller[17]. 
Cholesteryl [1-14C] oleate hydrolysis assay 
The following procedure was based on studies by 
Pittman and Steinberg[18] with some modifications. 
CholesterYl esterase activity was measured in pmol/ 
rain/rag protein by the release of [1-14C]-oleate from 
the substrate cholesteryl [l-14C]-oleate, using tri- 
tiated oleic acid as a means of ascertaining recovery 
of standard. Total volume of the reaction' mixture was 
kept constant at 0.34 ml. Contents of the reaction 
mixture included: Cofactor solution 150/*1; Buffer II 
100/*1; substrate cholesteryl [l-14C]-oleate _< 20/*1; 
and acetone (20/,l-volume of substrate). The amount 
of acetone was kept constant at 20/*l in each tube 
since at this assay volume, acetone in excess of 25 #l 
begins to have inhibitory effects on the enzyme. The 
assay was initiated by the addition of either 70 #l of 
Buffer II to control tubes or 0.091 mg enzyme to ex- 
perimental tubes. The reaction was terminated by the 
addition of 6 ml CHCIa-CHsOH (2:1, v/v) with vigor- 
ous vortexing, [9, 10-aH(N)]-Oleic acid [15/*g/20/*1, 
100,000 d.p.m.] was added to serve as a recovery stan- 
dard. Magnesium chloride (l.2ml, 0.0355/o soln) was 
then added to partition the mixture into an upper 
aqueous and lower organic phase. The bottom or- 
ganic layer was removed and evaporated to dryness 
under a stream of N 2 in a water bath at 37°C. The 
residues were redissolved in ether, 2 x 15 drops, 
which were spotted on Eastman Chromatogram silica 
gel plates. Plates were developed to a solvent front 
distance of  16 cm in hexane-diethyl ether-glacial ace- 
tic acid (80:20:1.75, v/v). A radioscan of the plates 
showed the substrate peak to be at R r = 0.64 and the 
product peak to be at Rp = 0.11. That portion of the 
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plate corresponding to the product, oleic acid, was 
removed and placed in liquid scintillation counting 
vials. Ethanol (1.5 ml, 95yo) was added and the vials 
slowly shaken for 5 min to elute activity from the 
plate. Toluene with 6g/I ppo and 0.075g/1 popop 
cocktail (10 ml) was added and vials were counted in 
a Packard liquid scintillation spectrophotometer at 
dual isotope settings which have been optimized to 
provide maximum isotope efficiency under the quench 
conditions encountered with this procedure, t*C and 
3H counts were converted to ~M.p.m." according to 
the equation for double isotope counting by Hen- 
dee[19]. All graphical plots were derived from the 
equation for a weighted fit of a linear regression de- 
scribed by Wilkinson[20]. 
[t :~ I]- 19-lodocholesteryl oleate hydrolysis assay 
The procedure for K,, determination of this sub- 
strate followed closely with that described above with 
a few exceptions. Cholesteryl esterase activity was 
measured by the release of [125i] _19_iodocholesterol 
from the substrate [~2sI]-19-iodocholesteryl oleate. 
TLC plates were spotted as above but developed in a 
solvent system of benzene--ethyl acetate (9:1, v/v). 
Under these conditions, the substrate peak appeared 
at R F --- 0,73 and the product peak at RF = 0.23. Por- 
tions of the plate representing both substrate and 
product peaks were cut and assayed for radioactivity 
in a Searle Model 1185 gamma counter. Counting 
efficiency for [~2~I] was 879,',. 
Competition a~,sa), 
Conditions for this assay followed that for the cho- 
lesteryl oleate hydrolysis assay except only one con- 
centration of cholesteryl [1-~*C]-oleate was used. 
Cholesteryl [I-t'~C]-oleate was added in a volume of 
lO,al to a final concentration of 67,aM. This concen- 
tration was chosen well within the plateau range of 
enzyme saturation according to the classical 
Michaelis--Menton concept, so that any variance in 
substrate concentration, from experimental error, 
would not significantly alter the velocity of the 
product formed. The inhibitor, 19-iodocholesteryl 
oleate was added in a volume of lO,al to final concen- 
trations of 65 and 325 vM. 
classical Lineweaver-Burk plots. Two parameters, V 
and Km were thus determined. 
An enzyme exhibits two types of specificity toward 
substrates, binding specificity as reflected in the KM 
values, and the kinetic specificity as reflected in the V 
values [21]. Since it is not uncommon for substrates 
to have similar K.~ values but vastly different V 
values [22] or the reverse, the most meaningful kin- 
etic constant for comparison of substrate specificity is 
the ratio V/KM [23]. 
The KM and V cholesteryl oleate were determined 
in six experiments and calculated to be 16.2 ltM -+ 3.4 
and 602pmol/min/mg protein +233 respectively. 
Large variations in cholesterol esterase activity have 
been reported previously by Pittman and Stein- 
berg[18]. They showed that KM values could vary 
from 4.2 to 63`aM and that the variation of V could 
be by as much as 50'~,i depending on the amount of 
lipid associated with the enzyme and the amount of 
ATP, cyclic AMP and protein kinase (EC 2.7.1.37} 
present in the preparations. Cholesterol ester hydroly- 
sis is stimulated by corticotropin via an adenylate 
cyclase, cyclic AMP, protein kinase pathway [23, 24] 
and consequently these variables along with the 
method of sacrifice of the animals (stress from ether 
anaesthesia raises corticotropin levels [25]) can 
greatly affect enzyme activity. 
We found that to optimize conditions and to get 
reproducible results we had to dialyze our prep- 
arations to remove lipid and activators from endo- 
genous protein kinase and then add back known 
amounts of ATE dibutyryl cyclic AMP and MgCI2. 
All ~," these factors are known to stimulate enzyme 
activity [18]. After optimizing the conditions of the 
assay, a kinetic study was performed on [~2~I]-19- 
iodocholesteryloleate. The Ku was calculated to be 
76.2 `aM and V 37,6 pmol/min/mg protein. 
To ascertain whether the iodinated ester was hy- 
drolyzed at the same active site as the normal sub- 
strate, a direct competition experiment was carried 
out in which 67`aM cholesteryl [1-~4C]-oleate was 
hydrolyzed in the presence of 65,aM and 325 #M of 
19-kMocholesteryl oleate. These concentrations of 
19-iodocholesteryl oleate caused a 20 and 49~',,/, inhibi- 
tion, respectively of [ 1 -~ *C]-oleic acid formation. 
R E S U L T S  
The velocity of hydrolysis was determined for 
iodinated and non-iodinated cholesteryl esters at 
varying concentrations of substrate. The reciprocal of 
the velocity was then plotted with respect to the reci- 
procal of the concentrations of the substrate to obtain 
D I S C U S S I O N  
On the basis of the kinetic data obtained for the 
two substrates, two qualitative statements can be 
made concerning the relative nature of the two sub- 
strates. As shown in Table l, the Ku  of 19-iodocholes- 
teryl oleate is only about four times greater than the 
Table I. Kinetic parameters 
Substrate V (pmol/min/mg) Ku (/JM) V/KM (ml/min/mg) 
Cholesteryl oleate 602.0 16.2 37.30 
19-Iodocholesteryl oleate 37.6 76.2 0.49 
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normal substrate, the binding specificity of this analog 
is roughly the same as the normal substrate. However, 
the V values indicate that the enzyme has a much 
greater kinetic specificity for the normal substrate. 
Moreover, when the parameters V/KM are compared 
(37.3 ml/min/mg protein for cholesteryl oleate and 
0.49 ml/min/mg protein for 19-iodocholesteryl oleate), 
it appears that the normal substrate is about 76 times 
more specific than the iodinated analog. Despite the 
lower kinetic specificity of 19-iodocholesteryl oleate, 
the competition experiment suggests that this iodin- 
ated compound competes for the same activity site as 
the normal ester. 
These findings offer one explanation for the ac- 
cumulation of 19-iodocholesterol in the adrenals and 
ovaries of animals and man. Once transported and 
stored in the esterified form in the endocrine organs, 
the 19-iodocholesterol esters remain unchanged 
because the enzyme cholesterol esterase has a lower 
binding specificity coupled with a significantly lower 
kinetic specificity for the iodinated ester. This concept 
is supported by the recent findings of Rizza et al.[5]. 
In their studies, rats were treated with either 
[131I]-19-iodocholesterol or [7-3HI-cholesterol. Cor- 
ticotropin, which increases steroid biosynthesis by 
activating cholesterol esterase [23, 24], was then ad- 
ministered to the rats. The corticotropin decreased 
the [7-3H]-cholesterol level in the lipid fraction but 
not that for [13q]-19-iodocholesterol. Although the 
authors did not establish the nature of the cholesterol 
present in the lipid fraction, it was undoubtedly esteri- 
fled as we have shown previously[I,  10]. These 
studies in conjunction with our own demonstrate that 
19-iodocholesteryl esters are much poorer substrates 
for cholesterol esterase than normal cholesteryl esters. 
In light of these findings, the ability of 19-radioiodin- 
ated cholesterol to selectively accumulate in the adre- 
nals and ovaries of animals is not surprising. 
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